These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 12746268)

  • 1. In vivo imaging with oligonucleotides for diagnosis and drug development.
    Tavitian B
    Gut; 2003 Jun; 52 Suppl 4(Suppl 4):iv40-7. PubMed ID: 12746268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives.
    Younes CK; Boisgard R; Tavitian B
    Curr Pharm Des; 2002; 8(16):1451-66. PubMed ID: 12052206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and applications of modified oligonucleotides.
    Gallo M; Montserrat JM; Iribarren AM
    Braz J Med Biol Res; 2003 Feb; 36(2):143-51. PubMed ID: 12563516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging and therapy -- a programme based on the development of new biomolecules.
    Haberkorn U; Eisenhut M
    Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1354-9. PubMed ID: 16133375
    [No Abstract]   [Full Text] [Related]  

  • 5. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo antisense imaging.
    Tavitian B
    Q J Nucl Med; 2000 Sep; 44(3):236-55. PubMed ID: 11105588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of a new [18F]fluoropyridine-based haloacetamide reagent for the labeling of oligonucleotides: 2-bromo-N-[3-(2-[18F]fluoropyridin-3-yloxy)propyl]acetamide.
    Kuhnast B; de Bruin B; Hinnen F; Tavitian B; Dollé F
    Bioconjug Chem; 2004; 15(3):617-27. PubMed ID: 15149190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular imaging of atherosclerotic plaques with technetium-99m-labelled antisense oligonucleotides.
    Qin G; Zhang Y; Cao W; An R; Gao Z; Li G; Xu W; Zhang K; Li S
    Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):6-14. PubMed ID: 15605287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotides: a new therapeutic approach.
    Temsamani J; Guinot P
    Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic oligonucleotides: a review].
    Wang X; Xian J; Chen G; Peng H
    Sheng Wu Gong Cheng Xue Bao; 2018 May; 34(5):664-675. PubMed ID: 29893074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular uptake and trafficking of antisense oligonucleotides.
    Crooke ST; Wang S; Vickers TA; Shen W; Liang XH
    Nat Biotechnol; 2017 Mar; 35(3):230-237. PubMed ID: 28244996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotracers for positron emission tomography imaging.
    Fowler JS; Ding YS; Volkow ND
    Semin Nucl Med; 2003 Jan; 33(1):14-27. PubMed ID: 12605354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo pharmacologic activities of antisense oligonucleotides.
    Mirabelli CK; Bennett CF; Anderson K; Crooke ST
    Anticancer Drug Des; 1991 Dec; 6(6):647-61. PubMed ID: 1663361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical pharmacology of antisense oligonucleotides.
    Marcusson EG; Yacyshyn BR; Shanahan WR; Dean NM
    Mol Biotechnol; 1999 Aug; 12(1):1-11. PubMed ID: 10554769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.